Retatrutide
LY3437943
Retatrutide is a novel triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors for superior metabolic effects. This innovative approach produces enhanced appetite suppression, improved insulin sensitivity, and increased energy expenditure, potentially delivering 20-25% weight loss in clinical trials.
Complete Research Database
0
Major Studies
0
Total Participants
3
Research Articles
N/A
Years of Research
Clinical Efficacy Data
Dose-response outcomes from controlled trials
6 Dose Levels Studied
Clinical Response by Dose
2.4%
Placebo
Control Group
11.2%
2.4 mg
17.8%
4.8 mg
20.9%
7.2 mg
24.2%
12 mg
24.2%
15 mg
★ Highest Dose
Comparative Response Chart
Placebo
2.4%
2.4 mg
11.2%
+8.8%
4.8 mg
17.8%
+15.4%
7.2 mg
20.9%
+18.5%
12 mg
24.2%
+21.8%
15 mg
24.2%
+21.8%
Source: Clinical research data from controlled trials
Medical Disclaimer
Retatrutide is currently in Phase 3 clinical trials and is not yet FDA approved. This information is for educational purposes only and should not replace medical advice. Consult with healthcare providers familiar with investigational therapies for personalized guidance. Side effects and contraindications are based on available clinical trial data.